BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 30022119)

  • 21. H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours.
    Dibitetto D; Liptay M; Vivalda F; Dogan H; Gogola E; González Fernández M; Duarte A; Schmid JA; Decollogny M; Francica P; Przetocka S; Durant ST; Forment JV; Klebic I; Siffert M; de Bruijn R; Kousholt AN; Marti NA; Dettwiler M; Sørensen CS; Tille JC; Undurraga M; Labidi-Galy I; Lopes M; Sartori AA; Jonkers J; Rottenberg S
    Nat Commun; 2024 May; 15(1):4430. PubMed ID: 38789420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.
    Barazas M; Annunziato S; Pettitt SJ; de Krijger I; Ghezraoui H; Roobol SJ; Lutz C; Frankum J; Song FF; Brough R; Evers B; Gogola E; Bhin J; van de Ven M; van Gent DC; Jacobs JJL; Chapman R; Lord CJ; Jonkers J; Rottenberg S
    Cell Rep; 2018 May; 23(7):2107-2118. PubMed ID: 29768208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H3K4 methylation by SETD1A/BOD1L facilitates RIF1-dependent NHEJ.
    Bayley R; Borel V; Moss RJ; Sweatman E; Ruis P; Ormrod A; Goula A; Mottram RMA; Stanage T; Hewitt G; Saponaro M; Stewart GS; Boulton SJ; Higgs MR
    Mol Cell; 2022 May; 82(10):1924-1939.e10. PubMed ID: 35439434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein phosphatase 1 acts as a RIF1 effector to suppress DSB resection prior to Shieldin action.
    Isobe SY; Hiraga SI; Nagao K; Sasanuma H; Donaldson AD; Obuse C
    Cell Rep; 2021 Jul; 36(2):109383. PubMed ID: 34260925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
    Zimmer J; Tacconi EMC; Folio C; Badie S; Porru M; Klare K; Tumiati M; Markkanen E; Halder S; Ryan A; Jackson SP; Ramadan K; Kuznetsov SG; Biroccio A; Sale JE; Tarsounas M
    Mol Cell; 2016 Feb; 61(3):449-460. PubMed ID: 26748828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
    Noordermeer SM; van Attikum H
    Trends Cell Biol; 2019 Oct; 29(10):820-834. PubMed ID: 31421928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. H4K20me2 distinguishes pre-replicative from post-replicative chromatin to appropriately direct DNA repair pathway choice by 53BP1-RIF1-MAD2L2.
    Simonetta M; de Krijger I; Serrat J; Moatti N; Fortunato D; Hoekman L; Bleijerveld OB; Altelaar AFM; Jacobs JJL
    Cell Cycle; 2018; 17(1):124-136. PubMed ID: 29160738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    Johnson N; Johnson SF; Yao W; Li YC; Choi YE; Bernhardy AJ; Wang Y; Capelletti M; Sarosiek KA; Moreau LA; Chowdhury D; Wickramanayake A; Harrell MI; Liu JF; D'Andrea AD; Miron A; Swisher EM; Shapiro GI
    Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17041-6. PubMed ID: 24085845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RIF1 acts in DNA repair through phosphopeptide recognition of 53BP1.
    Setiaputra D; Escribano-Díaz C; Reinert JK; Sadana P; Zong D; Callen E; Sifri C; Seebacher J; Nussenzweig A; Thomä NH; Durocher D
    Mol Cell; 2022 Apr; 82(7):1359-1371.e9. PubMed ID: 35216668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
    Wang J; Ding Q; Fujimori H; Motegi A; Miki Y; Masutani M
    Oncotarget; 2016 Feb; 7(7):7701-14. PubMed ID: 26713604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
    Talens F; Jalving M; Gietema JA; Van Vugt MA
    Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 53BP1 Enforces Distinct Pre- and Post-resection Blocks on Homologous Recombination.
    Callen E; Zong D; Wu W; Wong N; Stanlie A; Ishikawa M; Pavani R; Dumitrache LC; Byrum AK; Mendez-Dorantes C; Martinez P; Canela A; Maman Y; Day A; Kruhlak MJ; Blasco MA; Stark JM; Mosammaparast N; McKinnon PJ; Nussenzweig A
    Mol Cell; 2020 Jan; 77(1):26-38.e7. PubMed ID: 31653568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Shieldin - the protector of DNA ends.
    Setiaputra D; Durocher D
    EMBO Rep; 2019 May; 20(5):. PubMed ID: 30948458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
    Ip LR; Poulogiannis G; Viciano FC; Sasaki J; Kofuji S; Spanswick VJ; Hochhauser D; Hartley JA; Sasaki T; Gewinner CA
    Oncotarget; 2015 Apr; 6(12):10548-62. PubMed ID: 25868852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.
    Karakashev S; Fukumoto T; Zhao B; Lin J; Wu S; Fatkhutdinov N; Park PH; Semenova G; Jean S; Cadungog MG; Borowsky ME; Kossenkov AV; Liu Q; Zhang R
    Cancer Cell; 2020 Feb; 37(2):157-167.e6. PubMed ID: 32004442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
    Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
    Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.
    Hilmi K; Jangal M; Marques M; Zhao T; Saad A; Zhang C; Luo VM; Syme A; Rejon C; Yu Z; Krum A; Fabian MR; Richard S; Alaoui-Jamali M; Orthwein A; McCaffrey L; Witcher M
    Sci Adv; 2017 May; 3(5):e1601898. PubMed ID: 28560323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.